Kasichayanula, Sreeneeranj
Grover, Anita
Emery, Maurice G.
Gibbs, Megan A.
Somaratne, Ransi
Wasserman, Scott M.
Gibbs, John P.
Funding for this research was provided by:
Amgen
Article History
First Online: 20 January 2018
Compliance with Ethical Standards
:
: This work was supported by Amgen Inc.
: Drs. Somaratne and Wasserman are employees of and stockholders in Amgen, Inc. Drs. Somaratne and J.P. Gibbs are identified as inventors on at least one pending patent application owned by Amgen, Inc. relating to evolocumab. Dr. Wasserman appears on a number of pending patents owned by Amgen Inc. relating to evolocumab and PCSK9 inhibition. Drs. Kasichayanula, Grover, Emery, M. Gibbs, and J.P. Gibbs were employees of and stockholders in Amgen at the time this work was completed. Drs. Kasichayanula, M. Gibbs, and J.P. Gibbs are currently employed by AbbVie, Inc. Dr. Grover is currently employed by BioMarin Pharmaceutical Inc. Dr. Emery is currently employed by Seattle Genetics.